Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation
PHASE1CompletedINTERVENTIONAL
Enrollment
26
Participants
Timeline
Start Date
February 10, 2025
Primary Completion Date
March 28, 2025
Study Completion Date
May 6, 2025
Conditions
Healthy Volunteers
Interventions
DRUG
HSK39004
0.75\~4mg
DRUG
Placebo
0.75\~4mg
Trial Locations (1)
Unknown
Shandong Provincial Qianfoshan Hospital, Jinan
All Listed Sponsors
lead
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY
NCT06971198 - Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation | Biotech Hunter | Biotech Hunter